Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.
Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo JC, Pui CH, Relling MV, Evans WE. Galpin AJ, et al. Among authors: masson e. Mol Pharmacol. 1997 Jul;52(1):155-63. doi: 10.1124/mol.52.1.155. Mol Pharmacol. 1997. PMID: 9224825
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Giles FJ, List AF, Carroll M, Cortes JE, Valickas J, Chen BL, Masson E, Jacques C, Laurent D, Albitar M, Feldman EJ, Roboz GJ. Giles FJ, et al. Among authors: masson e. Leuk Res. 2007 Jul;31(7):891-7. doi: 10.1016/j.leukres.2006.12.001. Leuk Res. 2007. PMID: 17560285 Clinical Trial.
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M, Bhalla K. Giles F, et al. Among authors: masson e. Clin Cancer Res. 2006 Aug 1;12(15):4628-35. doi: 10.1158/1078-0432.CCR-06-0511. Clin Cancer Res. 2006. PMID: 16899611 Clinical Trial.
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
Thomas AL, Trarbach T, Bartel C, Laurent D, Henry A, Poethig M, Wang J, Masson E, Steward W, Vanhoefer U, Wiedenmann B. Thomas AL, et al. Among authors: masson e. Ann Oncol. 2007 Apr;18(4):782-8. doi: 10.1093/annonc/mdl469. Epub 2007 Jan 11. Ann Oncol. 2007. PMID: 17218488 Free article. Clinical Trial.
372 results